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Abstract
 Exercise-induced bronchoconstriction (EIB) is a pulmonary disorder mostly associated with 
athletes that causes acute airway narrowing during exercise. The treatment of choice is a 
short-acting beta agonist such as albuterol to assist with airway dilation, but this treatment 
has been inefficient in athletes who are exposed to inhaled irritants such as swimmers. The 
swimming world fears that repetitive albuterol use can give athletes a boost due to its side 
effects. Therefore, this review examines the use of inhaled corticosteroids (I) for 
management of symptoms such as wheezing and shortness of breath (O) in adolescent 
swimmers diagnosed with EIB (P) compared to the treatment of choice (C).
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● Exercise-induced bronchoconstriction (EIB) is a disorder related to athletes caused by the loss of heat 
and/or water from the airways during exercise from rapidly inhaled air that is drier than that of 
normal body air
● The general population diagnosed with EIB is approx. 5-20%, varying based on geographical location1
● Higher in locations where the air is dry, cold, and contains airway pollutants1
● Can be brought on by sports-related irritants, such as chlorine in swimmers or pollen from grasses on soccer fields
● Short acting beta-agonists (SABAs) such as Albuterol are currently considered the treatment of 
choice for intermittent asthma symptoms resembling EIB according to the American Thoracic 
Society2
● Inhaled corticosteroids such as fluticasone and beclomethasone are used as maintenance therapy for athletes whose 
EIB is not well controlled with a SABA. 
● Recently the swimming community has noticed that swimmers are taking multiple doses of the 
Albuterol inhalers due to failure of the treatment.
○ Their sympathetic nervous system-inducing side effects could potentially give the swimmers an advantage in the pool.
● Inhaled corticosteroids may be able to help with the swimmer’s EIB symptoms while also 








○ Published in peer-reviewed journal
○ Published within the last 5 years
○ Based upon case study, randomized control trial or cross sectional study
● Exclusion Criteria
○ Investigated other allergy symptoms such as eczema, psoriasis or cough 
○ Allergies to substances other than chlorine or swim-related substances 
○ Solutions to bronchoconstriction other than corticosteroids or beta-2-agonist inhalers 
○ Treatments for conditions other than exercise-induced bronchoconstriction 
○ Outside patient population of adolescent swimmers 
○ Meta-analyses or systematic reviews 
○ Patents or citations
Overall, both treatments (inhaled corticosteroids (ICS) and short-acting 
beta agonists (SABA)) improved patient’s symptoms of exercise-induced 
bronchoconstriction. Though only ⅙ studies compared side-by-side the 
efficacy of inhaled corticosteroids vs. short-acting beta-agonists in 
athletes. Therefore, it will be difficult to determine whether one treatment 
is superior to the other for such populations. 
• Strengths
○ Length of study




○ Study sample sizes
○ Blinding
• Future research
○ Using components of each of these studies to ultimately determine if 
ICS is a better treatment for swim athlete’s EIB symptoms
○ Genetic response to ICS treatment
○ Follow-up study determining the long-term effects of ICS treatment
Discussion 
Example Table
Up to 15 years Over 15 years
95% CI for 
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works 2.29 (.55) 45 2.00 (.17) 17 -.828, -.150 -2.87* 60
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in Adolescent Swimmers 
Although the evidence is strong for the benefits of ICS use in swimmers, there are factors that 
these studies did not consider
● Long-term impact of ICS on swim athletes
● Genetic consideration
Given the evidence from the studies analyzed, it is determined that swim athletes would likely 
benefit from the use of inhaled corticosteroids daily to help with long term care of their EIB
An inhaled corticosteroid plus or minus montelukast will be best used as a daily treatment 
regardless of whether an athlete would be performing an activity or not, and potentially use a 
beta-2-agonist or other treatment in acute situations, or active asthma exacerbation. 
Inhaled corticosteroids do not produce as many side effects as systemic corticosteroids, so there 
is low risk for harm in populations with sensitivities to these types of medications.
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Study Design Total N Age Range (Years) Duration of 
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Hoshino et al. (2015) Cohort 80 15-17
12-24 weeks ICS: Budesonide 800 
mcg daily (≥15 y/o)




, exhaled NO, 
IgE, atopy
Romberg et al. 
(2017)
CSS 187 13-20 2 days with one 
week between each 
day









Sastre et al. (2013) Case control 68 13-61 1 week with three 
separate visits




, FVC, exhaled 
NO, atopy, basophil 
count in sputum
Schafroth et al. 
(2014)
RCT 14 9-20 21 days
Budesonide 400 
mcg inhaled




, FVC, ECT, MCT
Simpson et al. 
(2015)
RCT 45 18-55 1 week with three 
separate visits
Terbutaline 500 mcg 
inhaled






Table 1. Comparison of Study Designs for Inhaled Corticosteroid vs. Beta-2-Agonist
